Complete response after avelumab maintenance therapy: successful management of metastatic urothelial carcinoma

Urothelial carcinoma is associated with high mortality despite significant progresses in treatment.In metastatic urothelial carcinoma the first-line treatment was recently changed, with enfortumab vedotin plus pembrolizumab being approved by the US Food and Drug Administration and European Medicines Agency. Until now, platinum-based chemotherapy and avelumab maintenance therapy for non-progressing tumours was the only standard of care for these patients.In the literature, few cases have been reported with complete response to avelumab maintenance therapy.